MedPath

etrozole versus hormone replacement therapy for frozen embryo transfer.

Not Applicable
Conditions
Health Condition 1: Z317- Encounter for procreative management and counseling for gestational carrier
Registration Number
CTRI/2023/06/053516
Lead Sponsor
one
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Women who will be undergoing frozen embryo transfer (FET)

Exclusion Criteria

Hydrosalpinx (not clipped or occluded); maternal medical disease; natural or modified natural FET cycles; cycles cancelled due to endometrial polyp, premature progesterone elevation or inadequate uterine blood flow.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Biochemical pregnacy rate, clinical pregnancy rate, abortion rateTimepoint: 4 weeks (At the end of ongoing frozen embryo transfer cycle), 8 weeks
Secondary Outcome Measures
NameTimeMethod
Endometrial thickness before transfer (mm). <br/ ><br>Serum Progesterone on day of transfer.Timepoint: 4 weeks (At the end of ongoing frozen embryo transfer cycle), 8 weeks
© Copyright 2025. All Rights Reserved by MedPath